Effectiveness of Y-90-antitenascin MAbs loco-regional radioimmunotherapy of malignant gliomas:: An ongoing phase II trial.

被引:0
|
作者
Riva, P
Franceschi, G
Frattarelli, M
Riva, N
Casi, M
Guiducci, G
Giuliani, G
Santimaria, M
Amato, M
Mäke, H
机构
[1] M Bufalini Hosp, Dept Nucl Med, Cesena, Italy
[2] M Bufalini Hosp, Dept Neurosurg, Cesena, Italy
[3] M Bufalini Hosp, Oncol Romagnolo 1, Cesena, Italy
[4] Kantonsspital Basel, Inst Nucl Med, Basel, Switzerland
来源
EUROPEAN JOURNAL OF NUCLEAR MEDICINE | 1999年 / 26卷 / 09期
关键词
D O I
暂无
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
OS34
引用
收藏
页码:969 / 969
页数:1
相关论文
共 21 条
  • [21] A phase I/II trial of radioimmunotherapy (RIT) with 90Yttrium-Ibritumomab tiuxetan (Zevalin®; 90Y-Zevalin) combined with the redox-active agent motexafin gadolinium (MGd):: Prompt and high remission rates in patients with rituximab-refractory non-Hodgkin's lymphoma (NHL)
    Evens, Andrew M.
    Spies, Stewart
    Patton, David
    Helenowski, Irene
    Jovanovic, Borko
    Miyata, Sarah
    Hamilton, Elizabeth
    Saville, M. Wayne
    Miller, Richard A.
    Winter, Jane N.
    Gordon, Leo I.
    BLOOD, 2007, 110 (11) : 754A - 754A